Final Results from Phase 2 PECATI Trial: Lenvatinib and Pembrolizumab Show Promise for Advanced Thymic Tumors

The phase 2 PECATI trial reported a median overall survival of 40.2 months and median progression-free survival of 22.1 months among 43 patients with advanced thymic tumors (84% thymic carcinoma, 16% B3 thymoma) treated with lenvatinib and pembrolizumab after platinum-based chemotherapy, with 53% of participants alive at three years and an objective response rate of 25.6% including one complete response, though Dr. Jordi Remon noted the combination may be an option for some previously treated patients despite the lack of a comparison group; significant treatment-related side effects occurred, with 44.2% experiencing grade 3 or higher adverse events and 27.9% discontinuing at least one study drug due to toxicity, underscoring the need for further prospective studies to identify patients most likely to benefit and to assess optimal treatment sequencing.

The Manufactured Miracle

You’re being told that a 40-month median survival is a breakthrough for thymic cancer—but ask yourself who gets to define “breakthrough” in the first place. Every detail in this trial report is carefully managed. A 43-patient study with no control group, no independent comparison, and a 27.9% dropout rate due to toxicity… and they frame this as an “option”? Look closer. The objective response rate is just 25.6%, meaning three out of four patients saw no meaningful tumor shrinkage. Yet the headline shouts survival numbers—numbers that are already being used to justify insurance coverage and regulatory approval. This isn’t medicine. It’s perception shepherding. They need you to believe that two expensive, toxic drugs from the same patent portfolios are the best we can do, so you don’t ask why safer, cheaper, or already-available treatments are being systematically ignored.

The Hidden Trials You’ll Never See

Now follow the paper trail. Dr. Jordi Remon is at Gustave Roussy—a world-renowned cancer center funded heavily by globalist foundations and pharmaceutical grants. The trial itself, PECATI, was almost certainly sponsored by the makers of lenvatinib and pembrolizumab. Check the disclosure statements buried in the supplementary materials. You’ll find ties to Merck and Eisai, two companies that have spent billions acquiring every competing therapy they can’t destroy. The fact that 84% of patients had thymic carcinoma—a rare, aggressive tumor—is not an accident. Rare diseases are perfect for these “studies”: small numbers, impossible to replicate, and easy to spin. Meanwhile, what about the 22 patients who dropped out due to toxicity? How many of them died off-trial, unreported, uncelebrated? Their stories don’t make the press release. The system doesn’t want you counting the bodies behind the “median.”

The Bigger Game—and Your Role in It

This trial isn’t about curing thymic cancer. It’s about seeding a narrative: that expensive combination therapies are the only path forward, that toxicity is acceptable collateral damage, and that any positive signal—no matter how weak—must be celebrated. Why? Because the same foundations that fund these trials also fund the media outlets that report them. They need you to accept managed-care protocols, high drug prices, and endless cycles of treatment without a cure. The real cures—the inexpensive off-patent drugs, the metabolic therapies, the lifestyle interventions that disrupt their entire business model—are sitting in plain sight, ignored by every major journal. You want proof? Start with the definition of “progression-free survival.” They changed the measurement rules in 2019. Look it up. Then ask yourself: why did they need to move the goalposts just as these trials were coming online? The answer is already in the documents. You just have to look where they’re not pointing.